NCT00240448已完成4 期
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,109
- 试验地点
- 100
- 主要终点
- Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
研究概览
简要总结
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg/hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg/hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent.
- •Age 18 years or older.
- •Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion).
- •Seated cuff DBP of 95 mmHg at Visit 2 (baseline).
排除标准
- •Pre-menopausal women (last menstruation 1 year prior to start of run-in period) who:
- •Are not surgically sterile and/or
- •Are nursing or pregnant
- •Are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of > 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine Device (IUD).
- •Known or suspected secondary hypertension.
- •Mean seated SBP >= 180 mmHg or mean seated DBP >= 120 mmHg during any clinic visit prior to randomization.
- •Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- •SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range, or
- •Serum creatinine > 3.0 mg/dL or creatinine clearance < 0.6 ml/sec.
- •Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
- •Clinically relevant hypokalemia or hyperkalemia.
- •Uncorrected volume depletion.
- •Uncorrected sodium depletion.
- •Primary aldosteronism.
- •Hereditary fructose intolerance.
- •Biliary obstructive disorders, cholestasis or moderate to severe hepatic insufficiency.
- •Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
- •History of drug or alcohol dependency within six months prior to start of run-in period.
- •Chronic administration of any medications known to affect blood pressure, etc.
- •Any investigational drug therapy within one month of start of run-in period.
- •known hypersensitivity to any component of the formulation study drugs (telmisartan, valsartan, HCT).
- •Contra-indication to a placebo run-in period (e.g. stroke within the past six months, MI, cardia surgery, PTCA or angina within the past three months prior to the start of run-in period.
- •Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan, valsartan, or HCT.
- •Night shift workers.
- •Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator.
- •NYHA functional class CHF III-IV.
- •Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve.
- •Patients whose diabetes has been unstable and uncontrolled for at least the past 3 months as defined by a HbA1c >/= 10%.
- •Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCT).
- •History of non-compliance with prescribed medication or protocol procedures.
结局指标
主要结局
Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
次要结局
- Percentage of responders based on change from baseline in cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period
研究者
研究点 (100)
Loading locations...
相似试验
已完成
4 期
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 HypertensionHypertensionNCT00168779Boehringer Ingelheim1,185
已完成
3 期
A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate HypertensionHypertensionNCT00133185Boehringer Ingelheim31
终止
4 期
SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk PatientsCoronary ArteriosclerosisHypertensionNCT00274105Boehringer Ingelheim22
已完成
4 期
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure MonitoringHypertensionNCT02242318Boehringer Ingelheim440
已完成
3 期
An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 MonotherapyHypertensionNCT01103960Boehringer Ingelheim324